Pharmaceutical firm Astellas has introduced its prodrug for isavuconazole, Cresemba (isavuconazonium sulfate), in the US.
Cresemba has been developed to treat adult patients with invasive aspergillosis and invasive mucormycosis or otherwise called zygomycosis.
Astellas Pharma US president Jim Robinson said: “This launch builds upon our strong heritage of bringing innovation and renewed hope to patients in need, including those affected by these devastating fungal infections.”
Cresemba is the prodrug that contains the active antifungal agent isavuconazole, an azole antifungal indicated to treat invasive aspergillosis and invasive mucormycosis.
In March this year, the company obtained approval from the US Food and Drug Administration (FDA) for its new drug application (NDA) to use Cresemba for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis.
Astellas global development head and divisional president Dr Bernie Zeiher said: “The launch of cresemba in the US marks the availability of an important new treatment option for patients and healthcare professionals fighting these life-threatening fungal infections.
“Given the high morbidity and mortality rates associated with invasive aspergillosis and invasive mucormycosis, we are excited to provide physicians and patients with this alternative therapy in an area of significant unmet medical need.”
Astellas noted that cresemba is being co-developed with Basilea Pharmaceutica International. In July 2014, Basilea submitted a European marketing authorisation application for cresemba to treat aspergillosis and invasive mucormycosis in adults.
Image: The photomicrograph reveals a mature sporangium of a Mucor sp. fungus that can be esponsible for mucormycosis. Photo: courtesy of CDC/Dr Lucille K Georg.